ReviewEuropean journal of endocrinology2022
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.
Review in European journal of endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Growth Hormone and Brain Regeneration: Evidence from Clinical Studies in Dementia, Traumatic Brain Injury, and Stroke: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Weekly long-acting growth hormone versus daily growth hormone therapy on quality of life, efficacy, and safety in children with short stature: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- The effect of growth hormone replacement therapy on craniopharyngioma recurrence: a systematic review and meta-analysis.Pituitary · 2025Pooled it
- Article
- Growth retardation in long-term high-risk neuroblastoma survivors treated with high-dose chemotherapy: the impact of large vertebral irradiation and gonadal damage.Bone marrow transplantation · 2026Article
- Approach to the patient with acquired hypothalamic syndrome.The Journal of clinical endocrinology and metabolism · 2026Review
- Multidisciplinary Management of Pediatric Craniopharyngioma: From Diagnosis to Long-Term Outcomes.Biomedicines · 2026Review
- Current Approaches and Therapeutic Strategies for Hypothalamic Syndrome in Patients with Childhood-onset Craniopharyngioma.Journal of clinical research in pediatric endocrinology · 2026Review
- Pharmacovigilance evaluation of somatrogon-associated adverse events in real-world databases.Endocrine connections · 2026Article
- Growth Outcomes and Relapse Risk in Pediatric Medulloblastoma Survivors with and Without Growth Hormone Therapy: A 23-Year Single-Center Cohort Study.Journal of clinical medicine · 2026Article
- Review
- Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026Review
- Retrospective analysis of growth hormone effects on growth and adenoma volume in children with pituitary microadenoma.Translational pediatrics · 2026Article
- Suprasellar CNS germ cell tumors and endocrine sequelae: early growth hormone therapy as a contributor to height gain: a single institute analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Distinct Glucose Profiles with Daily and Weekly Growth Hormone Therapy Revealed by Continuous Glucose Monitoring.Journal of the Endocrine Society · 2026Article
- Children with craniopharyngioma resection had better response to recombinant human growth hormone therapy than those with idiopathic short stature.Frontiers in endocrinology · 2026Observational
- The Central Control of Energy Metabolism: Hypothalamic Obesity Is Not One Disease.Hormone research in paediatrics · 2026Review
- Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma.Frontiers in endocrinology · 2026Review
- Endocrine and metabolic consequences of childhood-onset craniopharyngioma during the transition age: A literature review by the TALENT study group.Reviews in endocrine & metabolic disorders · 2025Review
- Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity.Endocrine reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 20 institutions in 18 countries.
Funding
Abstract
Growth hormone (GH) has been used for over 35 years, and its safety and efficacy has been studied extensively. Experimental studies showing the permissive role of GH/insulin-like growth factor 1 (IGF-I) in carcinogenesis have raised concerns regarding the safety of GH replacement in children and adults who have received treatment for cancer and those with intracranial and pituitary tumours. A consensus statement was produced to guide decision-making on GH replacement in children and adult survivors of cancer, in those treated for intracranial and pituitary tumours and in patients with increased cancer risk. With the support of the European Society of Endocrinology, the Growth Hormone Research Society convened a Workshop, where 55 international key opinion leaders representing 10 professional societies were invited to participate. This consensus statement utilized: (1) a critical review paper produced before the Workshop, (2) five plenary talks, (3) evidence-based comments from four breakout groups, and (4) discussions during report-back sessions. Current evidence reviewed from the proceedings from the Workshop does not support an association between GH replacement and primary tumour or cancer recurrence. The effect of GH replacement on secondary neoplasia risk is minor compared to host- and tumour treatment-related factors. There is no evidence for an association between GH replacement and increased mortality from cancer amongst GH-deficient childhood cancer survivors. Patients with pituitary tumour or craniopharyngioma remnants receiving GH replacement do not need to be treated or monitored differently than those not receiving GH. GH replacement might be considered in GH-deficient adult cancer survivors in remission after careful individual risk/benefit analysis. In children with cancer predisposition syndromes, GH treatment is generally contraindicated but may be considered cautiously in select patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.